StockNews.com started coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA – Free Report) in a research report sent to investors on Monday. The brokerage issued a hold rating on the biopharmaceutical company’s stock.
Separately, Cantor Fitzgerald boosted their price objective on shares of Vanda Pharmaceuticals from $11.00 to $13.00 and gave the company an overweight rating in a report on Thursday, August 1st.
Read Our Latest Report on VNDA
Vanda Pharmaceuticals Stock Performance
Vanda Pharmaceuticals (NASDAQ:VNDA – Get Free Report) last posted its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.12). The business had revenue of $47.46 million during the quarter, compared to the consensus estimate of $48.50 million. Vanda Pharmaceuticals had a negative net margin of 6.00% and a negative return on equity of 2.01%. Sell-side analysts forecast that Vanda Pharmaceuticals will post -0.49 EPS for the current year.
Institutional Trading of Vanda Pharmaceuticals
A number of institutional investors and hedge funds have recently made changes to their positions in VNDA. Raymond James & Associates bought a new stake in shares of Vanda Pharmaceuticals during the 4th quarter worth approximately $42,000. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Vanda Pharmaceuticals by 352.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,658 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 5,186 shares during the period. Mackenzie Financial Corp bought a new stake in shares of Vanda Pharmaceuticals during the 4th quarter worth approximately $46,000. Bailard Inc. bought a new stake in shares of Vanda Pharmaceuticals during the 4th quarter worth approximately $111,000. Finally, Pinnacle Wealth Planning Services Inc. bought a new stake in shares of Vanda Pharmaceuticals during the 4th quarter worth approximately $87,000. Institutional investors own 88.14% of the company’s stock.
About Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.
Further Reading
- Five stocks we like better than Vanda Pharmaceuticals
- What Are the U.K. Market Holidays? How to Invest and Trade
- Owens-Corning Stock: Good Value or Recession Red Flag?
- Using the MarketBeat Dividend Yield Calculator
- Datadog Exceeds Q2 Expectations, Solidifies Market Leadership
- NYSE Stocks Give Investors a Variety of Quality OptionsĀ
- Cybersecurity Stock Surges, Promising Double-Digit Gains
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.